Key takeaways
- ~8–10K Estimated US SMA prevalence; incidence ~1 in 10,000 live births · CureSMA / Prior TW, Genet Med 2010 (PMID 20057317)
- ~98% of SMA cases caused by biallelic SMN1 loss; SMN2 copy number sets severity · Prior TW, Genet Med 2010 (PMID 20057317)
- 13.6 mo median survival in untreated Type 1 SMA · Finkel RS et al., Neurology 2014 (PMID 25080519)
SMN2 copy number sets SMA severity across the Type 1–4 spectrum — and newborn screening has split the disease into pre-symptomatic and symptomatic populations with different treatment logic.
Spinal muscular atrophy is an autosomal-recessive motor-neuron disease caused by biallelic loss or mutation of SMN1, present in roughly 98% of cases. Severity is graded by the number of copies of the paralogous SMN2 gene, which produces a small amount of functional SMN protein: more SMN2 copies generally means a milder phenotype. US prevalence is estimated at 8,000–10,000 patients, with an incidence near 1 in 10,000 live births. The clinical spectrum runs from Type 1 (onset before six months, no independent sitting untreated) through Types 2 and 3 to the mildest Type 4 adult-onset form.
Two features define the modern landscape. First, natural history is severe at the Type 1 end: untreated, median survival is about 13.6 months, driven by rapid anterior-horn-cell loss in the first months of life, the window in which treatment matters most. Second, newborn screening has transformed detection: SMA was added to the federal Recommended Uniform Screening Panel in 2018, and all 50 states screen as of 2023, identifying roughly 300 infants a year before symptoms emerge. This creates two distinct populations (pre-symptomatic NBS-identified infants and older symptomatic patients) that call for different treatment strategies and drive different commercial segmentation.
SMA type spectrum — SMN2 copy number, onset, and clinical course
| Type | Typical SMN2 Copies | Onset | Share of Diagnoses | Defining Motor Feature | Untreated Course |
|---|---|---|---|---|---|
| Type 1 (Werdnig-Hoffmann) | 1–2 | <6 months | ~60% | Never sit unsupported | Median survival ~13.6 months without treatment |
| Type 2 | 3 | 6–18 months | ~27% | Sit, never walk | Survival to adulthood; respiratory and scoliosis burden |
| Type 3 (Kugelberg-Welander) | 3–4 | >18 months | ~13% | Walk, may lose ambulation | Near-normal lifespan; progressive weakness |
| Type 4 | 4+ | Adulthood | <5% | Mild proximal weakness | Normal lifespan |
| Pre-symptomatic (NBS-identified) | 2–3 (screened) | Detected at birth | ~300/yr (cross-type) | Asymptomatic at treatment | Near-normal development if treated early |
Sources: Prior TW, Genetics in Medicine 2010 (PMID 20057317); Finkel RS et al., Neurology 2014 — Type 1 natural history (PMID 25080519); CureSMA and the federal Recommended Uniform Screening Panel (RUSP) for newborn-screening coverage. SMN2 copy-number-to-phenotype mapping is a general genotype-phenotype correlation, not deterministic.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does SMN2 copy number map to SMA type and severity, and what does that mean for treatment selection? • • SMN1 deletion mechanism and SMN2 as the disease modifier • Type 1–4 phenotype by SMN2 copy number • Motor-milestone trajectory by type • How copy number and age gate therapy eligibility
- How has newborn screening changed the US SMA patient population and the pre-symptomatic treatment window? • • RUSP addition and 50-state screening timeline • ~300 pre-symptomatic diagnoses per year • Pre-symptomatic vs symptomatic outcome divergence • Downstream segmentation for gene therapy vs chronic therapy
- What is the untreated natural history of SMA across types, and where is the residual clinical burden? • • Type 1 survival and milestone data • Respiratory and motor decline by type • Burden in older Type 2/3 patients on chronic therapy • Emerging questions on long-term treated outcomes
What's inside
-
1 · SMA Genetics: SMN1 Loss & SMN2 Modification 4 pp
- Biallelic loss of SMN1 causes roughly 98% of SMA cases; SMN2 copy number is the modifier gene that sets phenotype severity
- Why more SMN2 copies generally means a milder phenotype, and how copy number becomes the treatment-selection axis
-
2 · US Epidemiology & the Type 1–4 Spectrum 5 pp
- US prevalence of roughly 8,000–10,000 patients, with incidence near 1 in 10,000 live births
- Type 1 accounts for roughly 60% of diagnoses, Type 2 about 27%, Type 3 about 13%, and Type 4 under 5%
-
3 · Natural History & Motor-Milestone Trajectory 4 pp
- Untreated Type 1 median survival is about 13.6 months, driven by rapid anterior-horn-cell loss in the first months of life
- Motor trajectory by type: Type 2 patients sit but never walk, Type 3 patients walk but may lose ambulation, Type 4 has near-normal lifespan
-
4 · Newborn Screening & the Pre-Symptomatic Population 5 pp
- SMA joined the federal RUSP in 2018; all 50 states screen as of 2023, identifying roughly 300 infants a year before symptoms emerge
- Pre-symptomatic NBS-identified infants achieve near-normal motor development when treated early, a distinct population from symptomatic patients
-
5 · Symptomatic Type 2/3 Burden & Chronic Management 4 pp
- Type 2 patients survive to adulthood but carry respiratory and scoliosis burden requiring chronic management
- Type 3 patients retain near-normal lifespan but face progressive weakness and possible loss of ambulation over time
-
6 · Treated Outcomes & Residual Unmet Need 4 pp
- Pre-symptomatic treatment produces near-normal motor development, but older Type 2/3 patients on chronic therapy still carry respiratory and scoliosis burden
- Where long-term treated-outcome data remains thin, particularly durability of effect and lifetime trajectory in NBS-identified infants
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Spinal Muscular Atrophy Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US SMA patient population. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
SMA disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and registry data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.
Key sources: Prior TW, Genet Med 2010 (PMID 20057317) for SMA genetics and prevalence; Finkel RS et al., Neurology 2014 (PMID 25080519) for Type 1 natural history; the federal Recommended Uniform Screening Panel and CureSMA for newborn-screening coverage; and FDA Drugs@FDA for approved-therapy context.
- Prevalence and genetics verified against Prior TW, Genet Med 2010 (PMID 20057317)
- Type 1 untreated survival verified against Finkel RS et al., Neurology 2014 (PMID 25080519)
- Newborn-screening coverage (RUSP 2018; 50 states 2023) verified against CureSMA and the federal RUSP
- SMN2 copy-number-to-severity relationship characterised as a genotype-phenotype correlation, not deterministic
Frequently asked questions
Genetics What causes spinal muscular atrophy and how is severity determined?
SMA is an autosomal-recessive motor-neuron disease caused in about 98% of cases by biallelic loss or mutation of the SMN1 gene. Severity is graded by the number of copies of the SMN2 gene, which makes a small amount of functional SMN protein — more SMN2 copies generally means a milder phenotype, spanning Type 1 (infantile, most severe) to Type 4 (adult-onset, mildest).
Epidemiology How common is SMA in the US and how many patients are found by newborn screening?
US prevalence is estimated at 8,000–10,000 patients, with incidence near 1 in 10,000 live births. Since SMA was added to the federal Recommended Uniform Screening Panel in 2018 (with all 50 states screening by 2023), roughly 300 infants a year are identified before symptoms appear, creating a pre-symptomatic population with markedly better outcomes when treated early.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.